You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Validation and Early Commercialization of the ENVISAGE Assay, a Prognostic Test for Barrett's Esophagus
SBC: CAPSULOMICS INC Topic: 300Barrett’s esophagus (BE) is the strongest known risk factor for, and obligate precursor of, esophageal high- grade dysplasia (HGD) and adenocarcinoma (EAC). However, determining future neoplastic progression risk is quite challenging in BE patients: current risk estimation is based solely on highly variable, subjective, observer-dependent histopathologic diagnoses (i.e., non-dysplastic (ND), Low ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury
SBC: PROTHERA BIOLOGICS, INC. Topic: 105Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD
SBC: CREATIVE BIO-PEPTIDES INC Topic: NIA7. Project Summary ADRD dementias account for up to 25% of all dementias in patients older than 65 years and there is strong evidence of co-morbid pathologies caused by (amyloid β (Aβ), tau and α-synuclein (αSyn). The degree of AD- related pathology in Lewy Body Dementias (LBD) is moderate or severe in 50% of PDD and more than 70% of DLB patients have concomitant AD-related pathology so that t ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Culture and amplification-free bacterial sepsis diagnosis
SBC: SCANOGEN INC. Topic: NIAIDCulture and amplification-free bacterial sepsis diagnosis Summary Sepsis is a life-threatening complication of an infection that requires immediate treatment. The identification of the causative microorganism utilizing processes based on blood culture is a keystone of sepsis diagnosis. However, blood culture takes one to five days to provide results. Here, we propose the development of a culture a ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeting LRRC8 signaling to prevent and treat arterial thrombosis in type 2 diabetes
SBC: Senseion Therapeutics, Inc. Topic: NHLBIProject SummaryCardiovascular disease (CVD) including stroke and myocardial infarction (MI), and Type 2 diabetes (T2D) areoverlapping global pandemics. CVD is the most common cause of death in patients with T2D and the economicburden of stroke and myocardial ischemia in patients with T2D is staggering. While newer glycemic controlagents like SGLT2 inhibitors and GLP1 agonists can help reduce CVD e ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of PTLS-209 for treatment for giardiasis
SBC: PRIMETIME LIFE SCIENCES, LLC Topic: NIAIDProject Summary: This project focuses on the development of treatment to combat giardiasis resistance to standard care drugs. Giardia lamblia is a highly infective waterborne parasite that causes severe diarrhea. Current antigiardiasis drugs fail in about 20% of cases, and they all have undesirable side effects. Additionally, drug-resistant G. lamblia strains can be readily raised in the laborator ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis
SBC: PROTHERA BIOLOGICS, INC. Topic: NICHDNecrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation
SBC: IMMUNOPHOTONICS INC Topic: 102Abstract: Immunophotonics is a biotech company developing a synthetic biopolymer, IP-001, to potentiate a systemic immunotherapy via microwave (MWA) thermal tumor ablation for treatment of Hepatocellular carcinoma (HCC). The goal of this SBIR Fast Track is to complete preclinical safety and efficacy testing to support an investigational new drug (IND) application based on the feedback from a meeti ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Mobile Three-Dimensional Screening for Cranial Malformations
SBC: PEDIAMETRIX INC. Topic: NIDCRABSTRACTDelayed identification of infant head malformation is causing unnecessary medical complications and societal costs. A critical challenge in the early detection is the absence of tools available to pediatric offices to perform quantitative head shape assessment during well-child visits. Delays in diagnosis limit the opportunity for early, less invasive and effective treatment options. In th ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Motorized Hand Exoskeleton for Stroke Rehabilitation
SBC: SPRINGWEAR, LLC Topic: NIDILRRThis Phase I SBIR project further develops and tests the motorized HandSOME exoskeleton for stroke rehabilitation. For stroke survivors, improvement of the paretic hand can result in functional improvement of the upper paretic limb. However, the probability of regaining functional use of the impaired hand is low. In comparison to proximal joints, hand function restoration is often delayed, and pat ...
SBIR Phase I 2023 Department of Health and Human ServicesAdministration for Community Living